ED
EDSA.US Edesa Biotech Inc
- Market cap
- USD 26.2M
- P/E
- -
- P/B
- 50.50x
- ROE
- -179.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is EDSA.US undervalued?
Graham numberThe Graham number of Edesa Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Edesa Biotech Inc fundamental analysis
No fundamental analysis for Edesa Biotech Inc yet.
Edesa Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study t…
Full company profileEdesa Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Edesa Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.27M | 228K | 212K | 411K | 329K | 500.00 | 0.00 | 0.00 | 0.00 | 0.00 | 67.9K |
| Gross Profit | 144K | -306K | -233K | 310K | 311K | -119K | -118K | -183K | -186K | -119K | -103K |
| Operating Income | -4.91M | -5.22M | -5.08M | -2.83M | -6.40M | -23.7M | -18.4M | -9.22M | -7.01M | -7.91M | -16.2M |
| EBITDA | -4.87M | -4.85M | -4.85M | -2.83M | -6.34M | -13.2M | -17.5M | -9.22M | -6.13M | -7.07M | -16.1M |
| Net Income | -5.03M | -5.03M | -5.04M | -2.72M | -6.36M | -13.3M | -17.5M | -8.37M | -6.17M | -7.19M | -15.8M |
| EPS | -24 | -211 | -11 | -4.15 | -5.18 | -7.73 | -8.37 | -2.93 | -1.93 | -1.27 | -1.76 |
| Balance Sheet | |||||||||||
| Total Assets | 12.9M | 7.72M | 11.8M | 5.72M | 10.8M | 14.6M | 11.6M | 8.89M | 3.81M | 13.5M | 12.7M |
| Total Liabilities | 624K | 321K | 493K | 462K | 1.65M | 1.53M | 2.18M | 1.84M | 1.83M | 1.08M | 3.91M |
| Shareholders' Equity | 12.3M | 7.40M | 11.3M | 5.26M | 9.11M | 13.1M | 9.39M | 7.05M | 1.98M | 12.5M | 8.81M |
| Cash & Short-term Investments | 11.4M | 6.57M | 10.3M | 5.03M | 7.21M | 7.84M | 7.09M | 5.36M | 1.04M | 10.8M | 10.3M |
| Total Debt | - | - | - | - | 164K | 99.3K | 19.0K | 94.5K | 19.9K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.51M | -4.70M | -4.62M | -4.85M | -4.99M | -13.7M | -12.3M | -6.64M | -4.89M | -7.32M | -9.58M |
| Capital Expenditure | 402K | 303K | 383K | 8.10K | 34.3K | 6.15K | 5.66K | 3.00 | 0.00 | 0.00 | 18.67 |
| Free Cash Flow | -4.91M | -5.00M | -5.00M | -4.85M | -5.02M | -13.7M | -12.3M | -6.64M | -4.89M | -7.32M | -9.58M |
| Ratios | |||||||||||
| ROE | -40.8% | -68.0% | -44.6% | -51.8% | -69.9% | -102.2% | -186.9% | -118.8% | -311.4% | -57.7% | -179.7% |
| ROA | -38.8% | -65.2% | -42.8% | -47.6% | -59.1% | -91.5% | -151.6% | -94.2% | -161.8% | -53.1% | -124.4% |
| Net Profit Margin | -395.2% | -2,203.7% | -2,378.6% | -662.3% | -1,935.6% | -2,668,630.0% | - | - | - | - | -23,319.1% |
| Debt to Equity | - | - | - | - | 0.02x | 0.01x | 0.00x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Edesa Biotech Inc dividends
Edesa Biotech Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Oct 11, 2023.
Who owns Edesa Biotech Inc
- Insiders 13.89%
- Institutions 41.78%
- Public & others 44.33%
- Shares outstanding 13.5M
- Free float 6.30M
Top funds holding EDSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 35.1K | 0.26% | -0.37% | Sep 2026 |
| Fidelity Total Market Index | 13.5K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 11.5K | 0.09% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 162.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding EDSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 828K | 6.12% | 0.00% | Jun 2026 |
| Rubric Capital Management LP | 670K | 4.96% | -2.62% | Jun 2026 |
| Perceptive Advisors LLC | 563K | 4.17% | 0.00% | Jun 2026 |
| Millennium Management LLC | 562K | 4.16% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 456K | 3.38% | +1,421.46% | Jun 2026 |
| Boxer Capital Management, LLC | 205K | 1.52% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 81.8K | 0.61% | -4.80% | Jun 2026 |
| Geode Capital Management, LLC | 80.9K | 0.60% | +4.96% | Jun 2026 |
| Jane Street Group LLC | 72.5K | 0.54% | -37.38% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 38.7K | 0.29% | +0.71% | Jun 2026 |
| State Street Corp | 38.0K | 0.28% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 35.4K | 0.26% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 31.5K | 0.23% | 0.00% | Jun 2026 |
| BlackRock Inc | 27.5K | 0.20% | -0.77% | Jun 2026 |
| Northern Trust Corp | 15.0K | 0.11% | 0.00% | Jun 2026 |
| Scotia Capital Inc | 14.4K | 0.11% | -9.15% | Jun 2026 |
| Two Sigma Investments LLC | 14.0K | 0.10% | 0.00% | Jun 2026 |
| UBS Group AG | 6.76K | 0.05% | +188.65% | Jun 2026 |
| SBI Securities Co Ltd | 3.51K | 0.03% | +0.09% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 2.60K | 0.02% | 0.00% | Jun 2026 |
Edesa Biotech Inc company profile
- Company name
- Edesa Biotech Inc
- Ticker
- EDSA.US
- ISIN
- CA27966L3065
- Exchange
- USA Stocks
- Listed since
- Nov 5, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- September
- Address
- 100 Spy Court, Markham, ON, Canada, L3R 5H6
- Phone
- 289 800 9600
- Website
- edesabiotech.com
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech Inc management
3- Dr. Pardeep Nijhawan FRCPC, M.D.CEO, Company Secretary & Director · born 1971
- Dr. Michael J. Brooks M.B.A., Ph.D.President · born 1979
- Mr. Peter John Weiler M.B.A, M.Sc.Chief Financial Officer · born 1969